PPO Prescription Drug Coverage: Formularies and Tiers

Prescription drug benefits within a PPO plan are governed by a structured formulary — a tiered list of covered medications that determines cost-sharing at the pharmacy counter. Understanding how formularies are built, how tiers function, and what drives a drug's placement on those tiers is essential for anyone comparing PPO plan options or managing ongoing medication costs. This page explains the mechanics of formulary design, the logic behind tier assignments, and the tradeoffs embedded in the system.

Definition and scope

A formulary is the official list of prescription drugs covered under a health insurance plan's pharmacy benefit. The term is sometimes used interchangeably with "drug list," though in regulatory and plan documents the term "formulary" carries a specific legal weight under federal standards established by the Affordable Care Act (ACA) (45 CFR §156.122) and, for Medicare PPO products, under Part D regulations administered by the Centers for Medicare & Medicaid Services (CMS).

In a PPO context, formulary coverage applies whether prescriptions are filled at in-network or out-of-network pharmacies, though cost-sharing differentials between those two settings can be significant. The scope of a formulary extends to brand-name drugs, generic equivalents, specialty biologics, and sometimes over-the-counter medications when prescribed by a licensed provider. ACA-compliant plans sold on the Health Insurance Marketplace are required to cover at least one drug in every United States Pharmacopeia (USP) category and class (CMS Essential Health Benefits Bulletin).

Core mechanics or structure

Formularies are organized into tiers — numbered levels that correspond to increasing drug cost and increasing enrollee cost-sharing. Most commercial PPO formularies use a 4-tier or 5-tier structure, though Medicare Part D PPO plans (Medicare Advantage PPO plans with drug benefits) commonly use a 5-tier or 6-tier framework as defined by CMS guidance.

The standard 4-tier commercial structure functions as follows:

Cost-sharing at each tier may also be subject to the plan's deductible. Some PPO plans apply the deductible only to Tiers 3 and above, exempting lower-tier generics from deductible accumulation. The plan's out-of-pocket maximum caps annual drug spending once the threshold is reached.

Formularies are not static. Under ACA rules (45 CFR §156.122(c)), plans may generally update formularies mid-year for reasons such as FDA safety actions, new generic entry, or drug discontinuation, but must provide 60 days' notice before removing a drug or moving it to a higher cost-sharing tier — with an exception for immediate removal when the FDA identifies a safety issue.

Causal relationships or drivers

Tier placement is not arbitrary. Four primary forces drive where a drug lands within a formulary.

1. Pharmacy Benefit Manager (PBM) contracts. Most insurers outsource formulary management to a PBM — organizations such as Express Scripts, CVS Caremark, or OptumRx. PBMs negotiate rebates directly with drug manufacturers. A manufacturer willing to pay a larger rebate can secure preferred (lower-tier) placement for its branded product, even when a therapeutically equivalent competitor exists. This rebate dynamic is documented in Federal Trade Commission investigations, including the FTC's 2024 report on PBM practices (FTC Interim Report on PBMs, July 2024).

2. Generic availability. When a drug's patent expires and generic versions enter the market, formularies typically shift the brand-name version upward in tier while placing the generic at Tier 1. FDA defines a generic as therapeutically equivalent when it meets bioequivalence standards set under the Hatch-Waxman Act (FDA Orange Book).

3. Clinical effectiveness and utilization management. Formulary committees — which by URAC and NCQA accreditation standards must include licensed pharmacists and physicians — evaluate comparative clinical evidence when placing drugs. A drug requiring prior authorization or step therapy protocol is typically assigned to a higher tier with additional process barriers.

4. Specialty drug classification. The absence of a federal statutory definition of "specialty drug" means each PBM applies its own threshold. Common benchmarks use a monthly cost of $600–$700 or higher as a trigger for specialty tier placement, a threshold referenced in CMS guidance for Part D plans.

Classification boundaries

Not every medication a prescriber writes for will appear on a formulary. Three boundary categories affect coverage access:

Formulary drugs are listed and covered at a defined tier with the associated cost-sharing.

Non-formulary drugs are not listed and are typically not covered except through an exception process. Under ACA regulations (45 CFR §156.122(c)(3)), enrollees have the right to request an exception to obtain a non-formulary drug at formulary cost-sharing if a prescribing provider certifies that the formulary alternatives are clinically inappropriate.

Excluded drugs represent a third category — drugs that federal law explicitly permits plans to exclude regardless of formulary structure. These include drugs for weight loss, cosmetic conditions, and fertility in non-ACA-governed plan types, though state mandates can expand coverage obligations for state-regulated fully insured plans.

The distinction between "non-formulary" and "excluded" is critical in the PPO appeal process: a non-formulary drug can often be obtained through exception or appeal, while a categorically excluded drug generally cannot.

Tradeoffs and tensions

Formulary design involves genuine structural tradeoffs that affect different enrollee populations differently.

Rebate optimization vs. lowest net patient cost. The rebate-driven formulary model can result in a higher-list-price, higher-rebate brand being preferred over a lower-cost therapeutic alternative. When an enrollee's cost-sharing is calculated on list price rather than net-of-rebate price, the enrollee pays more even though the insurer receives a manufacturer rebate. This dynamic is a central concern in ongoing FTC and Congressional scrutiny of PBM transparency (FTC Interim Report on PBMs, July 2024).

Formulary restrictions vs. prescriber autonomy. Step therapy and prior authorization requirements embedded in higher-tier placement create administrative friction for prescribers and delays for patients. The American Medical Association has documented that prior authorization burdens affect clinical decision-making, a concern also reflected in CMS rules limiting prior authorization timelines for Medicare Advantage plans (CMS Final Rule, February 2023).

Premium cost vs. formulary breadth. Plans with broader formularies and lower tier restrictions tend to carry higher premiums. Narrower formularies help control plan costs but reduce drug access flexibility — a fundamental tension also observed in the comparison between PPO and more restrictive plan types covered in the PPO vs. HMO analysis.

Common misconceptions

Misconception: Generic drugs are always covered at Tier 1.
Correction: Non-preferred generics — those without a preferred PBM contract — can be placed at Tier 2. Two generics of the same molecule from different manufacturers may sit on different tiers depending on PBM negotiations.

Misconception: A drug listed in the formulary is always covered.
Correction: Formulary listing means the drug is eligible for coverage, but utilization management tools — including step therapy, quantity limits, and prior authorization — can block or delay access even for listed drugs. These tools are distinct from tier placement.

Misconception: The formulary is identical for all PPO plans from the same insurer.
Correction: A single insurer may administer multiple formulary variants — an employer-sponsored plan's formulary can differ substantially from the same insurer's individual marketplace plan formulary. The employer-sponsored PPO and individual PPO plans often use different PBM contracts.

Misconception: Out-of-network pharmacy fills are not covered.
Correction: PPOs, by structural definition, extend some benefit coverage outside the network. Out-of-network pharmacy benefits typically exist but carry higher cost-sharing than in-network fills.

Formulary review checklist

The following elements represent information points that can be verified against a plan's Summary of Benefits and Coverage (SBC), Evidence of Coverage (EOC), or the insurer's online drug lookup tool before enrollment:

  1. Confirm the formulary tier count (4-tier, 5-tier, or 6-tier) and identify which tier covers the specific medications in question.
  2. Verify whether the plan applies the deductible to all tiers or only to Tiers 3 and above.
  3. Identify whether cost-sharing at each tier is a flat copay or a coinsurance percentage.
  4. Check whether specific medications carry prior authorization, step therapy, or quantity limit flags on the drug lookup tool.
  5. Confirm the out-of-network pharmacy cost-sharing differential relative to in-network fills.
  6. Identify the plan's formulary exception and appeals process for non-formulary drugs (required under 45 CFR §156.122).
  7. Check whether the plan uses a specialty pharmacy requirement for Tier 4 or Tier 5 drugs — some PPO plans require specialty drugs to be dispensed only through a designated specialty pharmacy.
  8. For Medicare PPO enrollees, verify that the Part D formulary has been reviewed under the CMS Formulary Reference File for the applicable plan year.

Reference table: standard tier structure

Tier Drug Category Typical Cost-Sharing Common Utilization Management
Tier 1 Preferred generics $0–$15 copay None
Tier 2 Non-preferred generics; preferred brands $30–$60 copay Minimal
Tier 3 Non-preferred brands $60–$120 copay or 20%–30% coinsurance Possible prior authorization
Tier 4 Specialty / biologics 25%–50% coinsurance Prior authorization, step therapy, quantity limits
Tier 5 (where used) Select specialty or non-covered brands 25%–50% coinsurance or non-covered Prior authorization; specialty pharmacy required

Cost-sharing ranges are structural illustrations based on CMS formulary design guidance and ACA regulatory frameworks — not plan-specific figures. Actual amounts vary by plan and are disclosed in the Summary of Benefits and Coverage.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)